VTCN1 and neoplasm: In addition, the authors verified the effectiveness of a triple combination of NGI-1, camsirubicin (a chemotherapeutic agent that increases the immunogenicity of tumor) and PD-L1 blockade in treating tumors in preclinical breast cancer models.125 To this end, targeting the immunosuppressive molecule B7-H4 would be a novel strategy for facilitating anticancer immunity.